Skip to Content
Merck
  • EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.

Molecular cancer research : MCR (2017-01-26)
Juraj Adamik, Shunqian Jin, Quanhong Sun, Peng Zhang, Kurt R Weiss, Judith L Anderson, Rebecca Silbermann, G David Roodman, Deborah L Galson
ABSTRACT

In multiple myeloma, osteolytic lesions rarely heal because of persistent suppressed osteoblast differentiation resulting in a high fracture risk. Herein, chromatin immunoprecipitation analyses reveal that multiple myeloma cells induce repressive epigenetic histone changes at the

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA, Targets no known mammalian genes
Sigma-Aldrich
MISSION® esiRNA, targeting human GFI1